A study to improve lumpectomy surgery with real-time imaging
Part of Cancer, Skin clinical trials.
This study tests a new imaging tool that helps surgeons see cancer margins in real time during a lumpectomy, aiming to reduce the need for a second surgery. It is for women with early-stage breast cancer who are planning a lumpectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You have been diagnosed with early-stage breast cancer (invasive cancer or DCIS) that has not spread to other parts of the body.
- You are scheduled to have a lumpectomy (breast-conserving surgery) to remove the cancer.
- You are able to read, understand, and sign a consent form in English.
- You have not had prior surgery for the same breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging tool that helps surgeons see if any cancer cells are left behind during a lumpectomy. It may reduce the need for a second surgery.
This study looks at a more personalized way to follow up after breast-conserving surgery (lumpectomy). It may use extra imaging scans to detect any return of cancer early, which could help you feel more secure and get treatment sooner if needed.
This study tests a device called LumiSystem that helps doctors check if all cancer cells are removed during breast cancer surgery. The goal is to see if using it improves surgery outcomes.
This trial tests a scanner that checks removed breast tissue during surgery to help surgeons remove all cancer the first time. If it works, fewer women may need a second operation.
This study tests a new type of mammogram that might give clearer pictures of breast tissue. It is for women who are either scheduled for breast surgery or getting a regular mammogram.
This trial tests a focused radiation treatment before surgery for early-stage breast cancer that is hormone receptor positive and HER2 negative. The goal is to give precise radiation only to the tumor, with the hope of reducing side effects and improving outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.